Why the study?
Are biomarkers of cardiac fibrosis comparable between patients with mild and advanced heart failure?
Are biomarkers of cardiac fibrosis comparable between patients with mild and advanced heart failure?
Biomarkers of cardiac fibrosis are similar across mild and severe heart failure, suggesting early fibrotic processes and supporting the investigation of antifibrotic therapies in mild heart failure.
Comparable fibrosis biomarkers across HF severities should not yet change practice; leaves open early antifibrotic intervention pending prospective validation.
Cardiac fibrosis plays an important role in the pathophysiology of heart failure. The authors sought to determine whether biomarkers of cardiac fibrosis for milder clinical degrees of heart failure are comparable to those of more advanced disease. Procollagen types I and III amino-terminal peptides (PINP and PIIINP) and type I collagen telopeptide (ICTP) were compared between aldosterone-antagonistnaive patients with heart failure and New York Heart Association class I or II (n=22/23) and class III or IV (n=42/3) symptoms. Median (interquartile) range concentrations of PINP (63.3 [44.2-88.8] vs 48.6 [37.8-74.9] microg/L), ICTP (7.0 [5.4-16.8] vs 6.5 [4.7-12.7] microg/L), and PIIINP (4.7 [3.2-7.0] vs 4.7 [2.9-7.3] microg/L) were comparable between patients with mild and moderate to severe disease, respectively. These data suggest that patients with mild heart failure may have similar degrees of cardiac fibrosis to patients with more severe disease and support the examination of antifibrotic therapy, including aldosterone antagonists, in milder degrees of heart failure.
No takes yet. Share an insight, caveat, or question.
Cavallari et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: